Its involvement in LS pathogenesis is supported by both genetic and immunological evidence, with studies highlighting ECM1 downregulation, the presence of anti-ECM1 autoantibodies, and its impact on fibrosis-related pathways. Here, ECM1 is linked to Leigh syndrome.